Curantil N75 tablets p / o 75mg, No. 40

- Treatment and prevention of ischemic cerebral circulation disorders.

- Encephalopathy.

- Primary and secondary prevention of coronary heart disease (CHD), especially with intolerance to acetylsalicylic acid.

- Prevention of arterial and venous thrombosis, as well as treatment of their complications.

- Prevention of thromboembolism after heart valve replacement surgery.

- Prevention of placental insufficiency in complicated pregnancy.

- As part of complex therapy for any microcirculation disorders.

The dose of the drug is selected depending on the severity of the disease and the patient's response to treatment.
Patients with coronary artery disease are recommended to take CurantilЃ N 75 1 tablet 3 times a day. If necessary, the daily dose can be increased under the supervision of a physician.
For the prevention and treatment of cerebrovascular accidents, as well as for the prevention of thrombosis, it is recommended to take CurantilЃ N 75 1 tablet 3-6 times a day. The maximum daily dose is 450 mg of dipyridamole (6 tablets).
The tablets should be taken on an empty stomach, without breaking or biting, with a small amount of liquid.
The duration of the course of treatment is determined by the doctor.

Active ingredient: dipyridamole - 75,000 mg;
excipients: lactose monohydrate, corn starch, gelatin, sodium carboxymethyl starch (type A), colloidal silicon dioxide, magnesium stearate, hypromellose (average viscosity 6 mPa x s), talc, titanium dioxide (E 171), macrogol 6000, quinoline yellow (E 104), simethicone emulsion.

- Acute myocardial infarction.

- Unstable angina.

- Common stenosing atherosclerosis of the coronary arteries.

- Subaortic stenosis.

- Decompensated heart failure.

- Arterial hypotension, collapse.

- Severe arterial hypertension.

- Severe heart rhythm disturbances.

- Chronic obstructive pulmonary disease.

- Chronic renal failure.

- Liver failure.

- Hemorrhagic diathesis.

- Diseases with a tendency to bleeding (peptic ulcer and duodenal ulcer, etc.).

- Hypersensitivity to the components of the drug.

Carefully. Due to the lack of sufficient experience in the use of the drug in children, it is not recommended to prescribe it to children under the age of 12 years.

Trade name: CurantilЃ N 75

International non-proprietary name:

dipyridamole

Dosage form:

film-coated tablets

Composition for 1 tablet
Active ingredient: dipyridamole - 75,000 mg;
excipients: lactose monohydrate, corn starch, gelatin, sodium carboxymethyl starch (type A), colloidal silicon dioxide, magnesium stearate, hypromellose (average viscosity 6 mPa x s), talc, titanium dioxide (E 171), macrogol 6000, quinoline yellow (E 104), simethicone emulsion.

Description: round flat-cylindrical film-coated tablets, yellow.

Pharmacotherapeutic group. Vasodilating agent.

ATX code: B01AC07.

Pharmacological properties

Pharmacodynamics.

It has an inhibitory effect on platelet aggregation, improves microcirculation, has a mild vasodilator effect.
Dipyridamole dilates arterioles in the coronary blood flow system, with increasing doses also in other parts of the circulatory system. However, unlike organic nitrates and calcium antagonists, the expansion of the larger coronary vessels does not occur. The vasodilating effect of dipyridamole is due to two different mechanisms of inhibition.
Suppression of adenosine uptake. In vivo, adenosine is found at a concentration of approximately 0.15-0.20 ?mol. This level is maintained due to the dynamic balance between ejection and recapture. Dipyridamole inhibits the uptake of adenosine by endothelial cells, erythrocytes and platelets. After the introduction of dipyridamole, an increase in the concentration of adenosine in the blood and an increase in adenosine-mediated vasodilation are found. At higher doses, platelet aggregation caused by adenosine is inhibited, and the tendency to thrombosis is reduced.
Inhibition of phosphodiesterase. The breakdown of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), which suppress platelet aggregation, occurs in platelets under the action of the corresponding phosphodiesterases. In high concentrations, dipyridamole inhibits both phosphodiesterases, in therapeutic concentrations in the blood - only cGMP-phosphodiesterase. As a result of stimulation of the corresponding cyclases, the power of cAMP synthesis increases.

Pharmacokinetics.

After a single oral administration of dipyridamole at a dose of 150 mg, its maximum plasma concentration (Cmax) averages 2.66 ?g / l. The absorption process is influenced by the conditions in the digestive tract. Dipyridamole is almost completely bound to plasma proteins. Dipyridamole is metabolized in the liver by binding to glucuronic acid. It is excreted in the bile in the form of a monoglucuronide.

Indications for use

- Treatment and prevention of ischemic cerebral circulation disorders.

- Encephalopathy.

- Primary and secondary prevention of coronary heart disease (CHD), especially with intolerance to acetylsalicylic acid.

- Prevention of arterial and venous thrombosis, as well as treatment of their complications.

- Prevention of thromboembolism after heart valve replacement surgery.

- Prevention of placental insufficiency in complicated pregnancy.

- As part of complex therapy for any microcirculation disorders.

Contraindications

- Acute myocardial infarction.

- Unstable angina.

- Common stenosing atherosclerosis of the coronary arteries.

- Subaortic stenosis.

- Decompensated heart failure.

- Arterial hypotension, collapse.

- Severe arterial hypertension.

- Severe heart rhythm disturbances.

- Chronic obstructive pulmonary disease.

- Chronic renal failure.

- Liver failure.

- Hemorrhagic diathesis.

- Diseases with a tendency to bleeding (peptic ulcer and duodenal ulcer, etc.).

- Hypersensitivity to the components of the drug.

Carefully. Due to the lack of sufficient experience in the use of the drug in children, it is not recommended to prescribe it to children under the age of 12 years.

Application during pregnancy and lactation
The use of the drug during lactation is possible only if the expected benefit from treatment outweighs the possible risk.

Method of administration and dosage The
dose of the drug is selected depending on the severity of the disease and the patient's response to treatment.
Patients with coronary artery disease are recommended to take CurantilЃ N 75 1 tablet 3 times a day. If necessary, the daily dose can be increased under the supervision of a physician.
For the prevention and treatment of cerebrovascular accidents, as well as for the prevention of thrombosis, it is recommended to take CurantilЃ N 75 1 tablet 3-6 times a day. The maximum daily dose is 450 mg of dipyridamole (6 tablets).
The tablets should be taken on an empty stomach, without breaking or biting, with a small amount of liquid.
The duration of the course of treatment is determined by the doctor.

Side effects
When using the drug in therapeutic doses, side effects are usually not pronounced and are transient.
From the side of the cardiovascular system: palpitations, tachycardia (especially in people taking other vasodilators), bradycardia, 'hot flashes' of blood to the face, coronary steal syndrome (when using the drug at a dose of more than 225 mg / day), lowering blood pressure (BP ).
From the digestive system: nausea, vomiting, diarrhea, pain in the epigastric region. Usually, these side effects disappear with longer use of the drug.
On the part of the blood and hemostasis system:thrombocytopenia, changes in the functional properties of platelets, bleeding. In very rare cases, increased bleeding during or after surgery.
Others: weakness, dizziness, a feeling of ear congestion, noise in the head, headache, facial flushing, arthritis, myalgia, rhinitis, allergic reactions (such as rash or urticaria).

Overdose
Symptoms: decreased blood pressure, angina pectoris, tachycardia, hot flashes, weakness and dizziness.
Treatment: induction of vomiting, gastric lavage, the appointment of activated carbon.

The dilating effect of the drug can be stopped by slow (50-100 mg / min) intravenous administration of aminophylline. If the symptoms of angina pectoris persist, sublingual nitroglycerin is prescribed.

Interaction with other medicinal products
Xanthine derivatives (coffee, tea) can weaken the vasodilating effect of dipyridamole.
The use of dipyridamole simultaneously with anticoagulants (heparin, thrombolytics) or acetylsalicylic acid increases the risk of hemorrhagic complications, which must be taken into account when used together.
Dipyridamole can enhance the effect of antihypertensive drugs.
Dipyridamole can weaken the anticholinergic properties of cholinesterase inhibitors.
Influence on the ability to drive vehicles and use mechanisms
When using CurantilaЃ N 75, the ability to drive vehicles and control mechanisms may be indirectly impaired, since a drop in blood pressure may result in a change in reaction.

Release form
Film-coated tablets, 75 mg. 10 or 20 tablets in blister packs [opaque white PVC film / aluminum foil]. 2 or 3 (20 tablets) or 5 (10 or 20 tablets) blisters together with instructions for use in a cardboard box.

Storage conditions
List B.
At a temperature not higher than 30 ? C.
Keep the medicinal product out of the reach of children!

Shelf life is
3 years.
Do not use after the expiration date printed on the package.

Terms of dispensing from pharmacies
Prescription.